Organization
University of Michigan Health System Comprehensive Cancer Center
14 abstracts
Abstract
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.Org: NSABP, Dana-Farber Cancer Institute, University of Michigan Health System Comprehensive Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Institute of Cancer Research,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, Cancer Research and Biostatistics, University of Kansas Medical Center, ASCO,
Abstract
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.Org: Exact Sciences Corporation, CRAB, Rabin Medical Center, Public Health Sciences Division, Department of Breast Medical Oncology,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.Org: Exact Sciences Corporation, Cancer Research and Biostatistics (CRAB), Seattle, WA, ASCO, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Loyola University Chicago Stritch School of Medicine,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.Org: Moffitt Cancer Center, Stanford Cancer Center, Washington University School of Medicine in St Louis, University of Washington and Fred Hutchinson Cancer Research Centre, Massachusetts General Hospital,
Abstract
Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).Org: PDS Biotechnology, Merck & Co., Inc., Lineberger Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, MUSC Hollings Cancer Center, Charleston, SC,
Abstract
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.Org: University of Michigan, Cancer Research and Biostatistics (CRAB), Seattle, WA, Eisai, Biovica International AB, American Society of Clinical Oncology,
Abstract
Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, Hospital Universitari Vall d'Hebron Research Institute, Roswell Park Cancer Institute,
Abstract
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, University of Colorado Health Science Center, University of California Los Angeles,
Abstract
Clinicogenomic analysis of rare histologic variants of pancreatic carcinoma: Undifferentiated carcinomas with and without osteoclast-like giant cells.Org: University of Michigan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Division of Hepatopancreatobiliary Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University of Michigan Health System Comprehensive Cancer Center,
Abstract
Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer.Org: University of Michigan, Fred Hutchinson Cancer Research Center, Beaumont Health, University of Michigan Health Management Research Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,
Abstract
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC).Org: University of Michigan, University of Michigan, Rogel Cancer Center, Henry Ford Cancer Institute, Detroit, MI, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, University of Michigan Health System Comprehensive Cancer Center,